整理 | GLP1减重宝典内容团队1 月 19 日,国家药品监督管理局药品审评中心信息显示,诺和诺德旗下 CagriSema 注射液新适应症临床获批,用于在低热量饮食和增加体力活动基础上,8 至 18 岁以下儿童及青少年的长期体重管理。这一进展,标志着 GLP-1 类药物竞争正式从成人肥胖,延伸至更具争议、也更具长期价值的青少年人群。从产业逻辑看,这是一次极具战略意味的推进。青少年肥胖不仅是体重...
Source Link整理 | GLP1减重宝典内容团队1 月 19 日,国家药品监督管理局药品审评中心信息显示,诺和诺德旗下 CagriSema 注射液新适应症临床获批,用于在低热量饮食和增加体力活动基础上,8 至 18 岁以下儿童及青少年的长期体重管理。这一进展,标志着 GLP-1 类药物竞争正式从成人肥胖,延伸至更具争议、也更具长期价值的青少年人群。从产业逻辑看,这是一次极具战略意味的推进。青少年肥胖不仅是体重...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.